C

Concord Biotech Ltd
BSE:543960

Watchlist Manager
Concord Biotech Ltd
BSE:543960
Watchlist
Price: 1 163.65 INR 5.11%
Market Cap: ₹121.7B

Relative Value

The Relative Value of one CONCORDBIO stock under the Base Case scenario is 1 318.83 INR. Compared to the current market price of 1 163.65 INR, Concord Biotech Ltd is Undervalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CONCORDBIO Relative Value
Base Case
1 318.83 INR
Undervaluation 12%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Multiples Across Competitors

CONCORDBIO Competitors Multiples
Concord Biotech Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Concord Biotech Ltd
BSE:543960
122.2B INR 10.9 37.8 27 31.6
US
Eli Lilly and Co
NYSE:LLY
948.8B USD 16 51.5 34.6 37.1
US
Johnson & Johnson
NYSE:JNJ
563B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
282.3B CHF 4.6 30.1 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
211.8B GBP 5.1 31.2 14.9 21.8
US
Merck & Co Inc
NYSE:MRK
288.1B USD 4.5 15.1 10.7 12.7
CH
Novartis AG
SIX:NOVN
223B CHF 5.1 19.9 12.5 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
98.2B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
IN
C
Concord Biotech Ltd
BSE:543960
Average P/E: 24.3
37.8
15%
2.5
US
Eli Lilly and Co
NYSE:LLY
51.5
54%
1
US
Johnson & Johnson
NYSE:JNJ
21
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.1
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.2
38%
0.8
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
CH
Novartis AG
SIX:NOVN
19.9
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
2%
6.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
C
Concord Biotech Ltd
BSE:543960
Average EV/EBITDA: 44.1
27
18%
1.5
US
Eli Lilly and Co
NYSE:LLY
34.6
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
14.9
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
CH
Novartis AG
SIX:NOVN
12.5
6%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
1%
9.3
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
C
Concord Biotech Ltd
BSE:543960
Average EV/EBIT: 92.4
31.6
17%
1.9
US
Eli Lilly and Co
NYSE:LLY
37.1
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.9
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
21.8
23%
0.9
US
Merck & Co Inc
NYSE:MRK
12.7
8%
1.6
CH
Novartis AG
SIX:NOVN
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3